

The problem of catheter encrustation

A. W. Bruce, M.B., CH.B., F.R.C.S. (Edin. & Eng.), F.R.C.S. [C], F.A.C.S., S. S. Sira, M.B., CH.B., F.R.C.S. (Eng.), A. F. Clark, PH.D. and S. A. Awad, M.B., CH.B., F.R.C.S. [C], Kingston, Ont.

Summary: Catheter encrustation was studied in a group of long-stay hospital patients using both latex and silicone catheters. Moisture accounted for 80% by weight of the encrusted material with both catheters. Of the dry weight 90% was composed of protein, calcium, phosphorus, magnesium and uric acid. No relationship was found between the amounts of these substances in the urine and in the encrusted material. High levels of calcium, phosphorus and magnesium were found in the encrusted material from patients infected with *Proteus* organisms. No direct relationship was found between the duration of catheter drainage and the degree of encrustation, and there was a variation in patient susceptibility to encrustation irrespective of the catheter material. There was significantly less encrustation associated with silicone catheters.

Résumé: Le problème de l'incrustation des cathéters

Nous avons étudié le problème de l'incrustation des cathéters chez un groupe de malades hospitalisés depuis longtemps et qui étaient porteurs de sondes en latex et en silicone. La substance incrustée, dans les deux types de cathéters, comportait en poids, 80% d'eau. Quant au poids à sec, 90% était composé de protéine, de calcium, de phosphore, de magnésium et d'acide urique. Il n'a pas été possible d'établir une relation entre les quantités de ces substances dans l'urine et la substance incrustée. On a noté de fortes concentrations de calcium, de phosphore et de magnésium dans la substance incrustée chez les malades souffrant d'infections par des organismes du genre *Proteus*. On n'a pu établir de relation directe entre la durée du drainage par sonde et le degré de l'incrustation. De plus, on notait des variations dans la sensibilité du malade à l'incrustation, indépendamment de la nature de la matière dont était fait le cathéter. Cependant, on remarquait une incrustation nettement moindre chez les malades porteurs d'un cathéter en silicone.

Much has been written in recent years on the subject of catheter care and the prevention and control of urinary tract infection when indwelling catheters are used. In addition, there has been a marked improvement and refinement in the materials used in making catheters. Despite these advances, encrustation and the formation of bladder calculi is still a problem with patients on long-term indwelling catheter drainage. Encrustation attending the use of the more inert catheter materials now available has received relatively little attention, although there have been articles advocating the use of Renacidin® and methylene blue in prophylaxis.^{1,2} Barnhouse³ in 1968 reported his experience with formation of *in vitro* precipitates on foreign bodies in sterile and infected urines and found that, apart from the influence on pH, bacteria did not directly affect crystallization in urine. In 1972 Srinivasan and Clark⁴ reported their study comparing encrustation *in vitro* with different catheter materials; they found less encrustation with plastic and silicone than with latex and teflon in both sterile and infected urines. Painter *et al.*⁵ in a study of mucosal reaction to different catheter materials, found less reaction to teflon and silicone-coated latex, and at the 1973 American Urological Association meeting they reported the pure silicone catheter to be even less reactive.

We have had the opportunity to study catheter encrustation in two groups of long-staying patients in a chronic care hospital. The 20 patients of the first group were submitted to equal periods of drainage by both a

latex and pure silicone catheter, then the weight and calcium content of the encrustation were determined. The second group of 14 patients was studied in the same manner but detailed analysis of the encrusted material was carried out. The purposes of the study were: (a) to show the difference in degree of encrustation with silicone and latex catheters; (b) to identify the composition of the encrusted material; and (c) to study the factors responsible for the encrustation.

Methods

The following studies were carried out: urinalysis and culture of urine; and chemical analysis of blood, 24-hour urine samples and catheter encrustation.

For detailed analysis segments of catheters with encrusted material were weighed in the wet and dry state and then washed in several solutions, distilled water, saline 0.9%, ammonium hydroxide 10% and hydrochloric acid 5%, heated for 30 minutes at 65°C and centrifuged. The supernatants were analysed for protein, calcium, phosphorus, magnesium, uric acid, sodium, potassium, chloride, creatinine and urea nitrogen. The dry weight of the catheter plus the residual sediment was ascertained, as well as the dry weight of the catheter after the sediment had been scraped off (Fig. 1).

Results

All patients studied had alkaline urine and all cultures grew multiple





FIG. 1—Diagrammatic illustration of methodology used to identify encrusted material in silicone and latex catheters.



SILICONE LATEX

FIG. 2 — Typical difference in degree of encrustation between silicone and latex catheters after equal periods of use.

From the Departments of Urology and Biochemistry, Queen's University, Kingston

Reprint requests to: Dr. A. W. Bruce, Department of Urology, Queen's University, Kingston, Ont. K7L 3N6

organisms. No antibiotics were administered during the study.

Group 1

Fig. 2 illustrates the marked difference in degree of encrustation between a latex and a silicone catheter after equal periods of use in the same patient. Although the duration of drainage varied widely in this group, in each patient it was identical for the two types of catheter. Fig. 3 shows the relative weights of encrusted material in the two types of catheter and the number of days each catheter was in place. Three points would appear significant:

1. The weight of encrusted material is significantly greater with the latex catheter.
2. There is no direct relationship between the duration of catheter drainage and the degree of encrustation.
3. Irrespective of catheter material there is a marked variation in patient susceptibility to encrustation.

The calcium content of the encrustation was also much higher for the latex catheters (Fig. 4).

Group 2

In this group each patient had undergone a two-week period of drainage with each type of catheter. Moisture accounted for 80% of the weight of the encrusted material in both silicone and latex catheters (Fig. 5). The mean weight of encrusted material was significantly greater with the latex catheters.

Fig. 6 compares the mean dry weights of encrusted material and the proportions of material identified. Approximately 30 to 40% of the dry material was eluted by the methodology used, so that about 12% by total weight of the encrusted material remained unidentified. The relative proportions of

the different materials identified in the dried encrustation are shown in Fig. 7; protein, calcium, phosphorus, magnesium and uric acid formed approximately 90% of the total identified dry weight, and sodium, potassium, chloride, creatinine and urea nitrogen made up the remaining 7 to 10%. There appears to be no great variation in the relative proportions of these constituents with the two catheter materials. Their mean weights are shown in Fig. 8. Again, the larger absolute weights of these substances are associated with the latex catheters. It is interesting to note that the relative proportions of protein, magnesium and uric acid are approximately equal with the two types of catheter, but the calcium and phosphorus proportions are disproportionately high with the latex material.

It is said that one factor influencing the amount of encrustation is the solute content of the urine. In this study we

could find no correlation between the amounts of calcium, phosphorus, magnesium and uric acid in the urine and in the encrusted material. However, Fig. 9 shows a linear relationship between the relative concentrations of protein in the encrustation and urine with both types of catheter, particularly the silicone.

Proteus organisms were cultured in seven of the fourteen patients, and in six of the seven, high levels of calcium, phosphorus and magnesium were found in the encrustation. Presumably the urea-splitting property of the organisms is a factor in the precipitation of these inorganic substances.




FIG. 4—Relative weights of calcium in silicone and latex catheters after equal periods of drainage.




FIG. 5—Total mean weight, moisture content and dry weight of encrusted material in silicone and latex catheters.




FIG. 6—Mean weights of unidentified and identified material composing dry encrustation in silicone and latex catheters.




FIG. 7—Mean proportions of major identified constituents of dry encrustation.




FIG. 8—Mean weights of major identified constituents of dry encrustation in silicone and latex catheters.




FIG. 9—Correlation of protein content of urine (24-hour sample) and encrusted material in silicone and latex catheters.




FIG. 3—Relative weights of encrusted material in silicone and latex catheters and number of days each type of catheter was in place.

'ELAVIL PLUS'



Neuroleptic-Antidepressant

INDICATIONS: 'ELAVIL PLUS'* (amitriptyline hydrochloride and perphenazine) is indicated in patients with anxious or agitated depression. It is particularly indicated in patients with depression associated with marked psychomotor unrest and anxiety. It has also been found useful in some schizophrenic patients who have associated symptoms of depression. 'ELAVIL PLUS'* has been used in depressed patients, suffering from marked agitation, anxiety and tension, who may respond to the combination of a phenothiazine with amitriptyline.

DOSAGE SUMMARY: Keep in mind indications, management considerations, dosage schedules and attention to tolerance and response of patients to either perphenazine or amitriptyline. The usual initial dose of 'ELAVIL PLUS'* is one tablet three or four times a day, individualized according to the need and response of the patient, not exceeding 9 tablets per day. Dosage for children not established. Sedative effect is rapidly apparent, the antidepressant effect is delayed. After a satisfactory response is noted, dosage should be reduced to the smallest amount necessary to obtain relief from the symptoms.

CONTRAINDICATIONS: Central nervous system depression from drugs (barbiturates, alcohol, narcotics, analgesics, antihistamines); bone marrow depression; known hypersensitivity to phenothiazines or amitriptyline; during the acute recovery phase following myocardial infarction, and in the presence of acute congestive heart failure; patients receiving guanethidine or similarly acting compounds. Do not give concomitantly with MAOI drugs. Allow minimum of 14 days between therapies, then initiate therapy with 'ELAVIL PLUS'* cautiously, with gradual increase in dosage until optimum response is achieved.

WARNINGS: Tricyclic antidepressant drugs including amitriptyline particularly when given in high doses have been reported to produce arrhythmias, sinus tachycardia, and prolongation of the conduction time. A few instances of unexpected death have been reported in patients with cardiovascular disorders. Myocardial infarction and stroke have also been reported with drugs of this class. Therefore, these drugs should be used with caution in patients with a history of cardiovascular diseases such as myocardial infarction and congestive heart failure. Patients on 'ELAVIL PLUS'* should be cautioned against driving a car or operating machinery or apparatus requiring alert attention. Use cautiously in patients with history of urinary retention, glaucoma, or convulsive disorders. 'ELAVIL PLUS'* is not recommended for use in children or pregnant patients.

PRECAUTIONS: Suicide is a possibility in seriously depressed patients and may remain until significant remission occurs; this type of patient should be closely supervised, especially during the early phase of therapy. Patients should be cautioned against errors of judgement attributable to change in mood, and also of possible increased response to alcohol. Observe caution when administering to patients who have previously exhibited severe adverse reactions to other phenothiazines. The antiemetic effect of perphenazine may obscure signs of toxicity due to overdosage of other drugs or render more difficult the diagnosis of disorders such as brain tumors or intestinal obstruction. Discontinue the drug in the event of signs of individual intolerance to perphenazine. If hypotension develops, epinephrine should not be used. To avoid possible potentiation of action of any of the central nervous system depressants or atropine in concurrent therapy, reduce dosage of 'ELAVIL PLUS*'. Antidepressant medication may provoke mania or hypomania in manic-depressive patients; the likelihood of this seems to be reduced by the tranquilizing component of 'ELAVIL PLUS*'.
ADVERSE REACTIONS: Similar to those reported with either constituent alone.
Perphenazine: Behavioural: Oversedation, impaired psychomotor function, paradoxical agitation or excitement and aggravation of psychotic symptoms; catatonic like states, lassitude, insomnia, bizarre dreams and toxic confusional states. **Neurological:** Extrapyrmidal symptoms (opisthotonos, oculogyric crisis, hyperreflexia, dystonia, akathisia, dyskinesia, parkinsonism) the incidence and severity of which vary, usually are controlled by concomitant use of effective antiparkinsonian drugs, such as bntropine mesylate, and/or reduction in dosage,

but sometimes may persist after discontinuation of the phenothiazine. Parasthesias, slowing of the EEG, disturbed body temperature, muscle weakness and convulsions also reported.

Autonomic: Dry mouth, constipation, urinary frequency, blurred vision, and nasal congestion may occur. **Cardiovascular:** Severe, acute hypotension, of particular concern in patients with mitral insufficiency or pheochromocytoma; ECG abnormalities (quinidine-like effect), changes in pulse rate and cutaneous vasodilatation also reported. **Toxic and Allergic:** The phenothiazine compounds have produced blood dyscrasias (pancytopenia, thrombocytopenic purpura, leukopenia, agranulocytosis, eosinophilia); and liver damage (jaundice, biliary stasis). These have not been observed with perphenazine. Skin disorders (photosensitivity, itching, contact dermatitis, erythema, urticaria, eczema, up to exfoliative dermatitis), as well as other allergic reactions (asthma, laryngeal edema, angioneurotic edema, anaphylactoid reactions) have occurred.

Endocrine and Metabolic: Disturbances in the menstrual cycle, lactation, swollen breasts, failure of ejaculation, reduced sexual urge in the male, increased sexual urge in the female, pseudo-pregnancy, infertility, and glycosuria. Increased appetite, weight gain, hyperglycemia, altered cerebrospinal fluid proteins, peripheral edema. **Ophthalmological:** Centrally located stellate cataracts, corneal opacities, pigmentation of the conjunctiva, cornea or lens, lacrimation and kerato-conjunctivitis reported following use of phenothiazines; pigmentary retinopathy occurred with some phenothiazines with a piperidyl-ethyl side chain. **Miscellaneous:** Other adverse reactions reported with various phenothiazine compounds include gastrointestinal effects such as nausea, vomiting and heartburn; potentiation of CNS depressants; headache; and cerebral edema.

Amitriptyline hydrochloride: Behavioural: Activation of latent schizophrenia; high doses may cause temporary confusion or disturbed concentration, or rarely, transient visual hallucinations; hypomanic reactions; drowsiness which usually disappears with continuance of therapy; insomnia, giddiness, restlessness, agitation, fatigue, nightmares, disorientation, delusions, excitement, anxiety and jitteriness. **Neurological:** Epileptiform seizures; numbness, tingling, paresthesias of the limbs including peripheral neuropathy; dizziness, fine tremor, headache, ataxia, seizures, alteration in EEG patterns, extrapyramidal symptoms, tinnitus and incoordination; severe tremor only observed in high doses. **Autonomic:** Evidence of anticholinergic activity, such as urinary retention, reversible dilatation of the urinary tract, constipation, and more rarely, paralytic ileus of particular concern in the elderly; dry mouth, blurred vision and disturbance of accommodation.

Cardiovascular: A quinidine-like effect and other reversible ECG changes such as flattening or inversion of T waves, and bundle branch block; orthostatic hypotension, and with toxic doses, ventricular tachycardia and fibrillation have occurred. A few instances of unexpected death have been reported in patients with cardiovascular disorders. Myocardial infarction and stroke have also been reported with drugs of this class. **Toxic and Allergic Effects:** Bone marrow depression including agranulocytosis, eosinophilia, purpura and thrombocytopenia; jaundice rarely. Allergic type reactions manifested by skin rash, urticaria, photosensitization or swelling of the face and tongue and itching occurred rarely.

Gastrointestinal: Nausea, epigastric distress, heartburn, vomiting, anorexia, stomatitis, peculiar taste, diarrhea, parotid swelling, black tongue. **Endocrine:** Testicular swelling and gynecomastia in the male, breast enlargement and galactorrhea in the female, increased or decreased libido, elevation and lowering of blood sugar levels. **Metabolic:** Increased appetite, weight gain or weight loss in some patients. **Ophthalmologic:** Precipitation of latent glaucoma or aggravation of existing glaucoma; blurred vision and mydriasis. **Miscellaneous:** Other side effects that may occur include fainting, weakness, urinary frequency, increased perspiration, and alopecia. **Withdrawal Symptoms:** Abrupt cessation of treatment after prolonged administration may produce nausea, headache, and malaise; these are not indicative of addiction.

PRODUCT CIRCULAR AVAILABLE ON REQUEST
HOW SUPPLIED: Ca 3311 - Tablets
'ELAVIL PLUS*', orange, triangular, each containing 2 mg. of perphenazine and 25 mg. of amitriptyline hydrochloride, are supplied in bottles of 50 and 500.

(MC-851)

* Trademark



**MERCK
SHARP
& DOHME**

CANADA LIMITED/LIMITÉE

Where today's research is tomorrow's therapy

Discussion and conclusions

The results of our *in vivo* studies agree with those of the *in vitro* studies of Srinivasan and Clark.⁴ Encrustation is less likely to occur with silicone catheters than with latex catheters. Although this study was carried out in a series of patients with infected urine, it is believed that this would also apply to patients with sterile urine. It would seem reasonable to suggest that for long-term catheterization silicone has advantages over latex.

Possible explanations for the superiority of the silicone catheter are as follows: (1) the smooth, nonsticky surface reduces the adsorption of material to, and its absorption by the catheter; (2) the inert material produces less mucosal reaction; and (3) the lumen is larger.

Our methodology failed to identify 12% of the total encrustation. This proportion may consist of (a) cellular material (not appearing as protein), (b) denatured protein, and (c) other chemicals such as trace metals, e.g. zinc.

The absence of any relationship between duration of catheter drainage and degree of encrustation supports the concept of Howard *et al*⁷⁻⁸ of inhibitors in the urine, and we suggest they may be a defence against encrustation on a foreign body. This situation is comparable to that of stone-formers and non-stone-formers who have similar urinary calcium concentrations. In this study inhibitors of urinary deposits, such as orthophosphates and citrate, were not measured.

We intend to carry out further studies with similar patients to establish the mode of formation of the encrustation and to attempt a more complete chemical analysis.

We wish to thank Dr. W. Williams for his guidance, and Baxter Laboratories of Canada for their financial support.

References

- MULVANEY WP, HENNING DC: Solvent treatment of urinary calculi; refinements in technique. *J Urol* 88: 45, 1962
- LANGSTON JB, WILLIAMS RW, HOGG M: Inhibition of catheter encrustation and bladder calculi formation by oral administration of methylene blue (abstract 1339). *Fed Proc* 29: 1970
- BARNHOUSE DH: In vitro formation of precipitates in sterile and infected urines. *Invest Urol* 5: 342, 1968
- SRINIVASAN V, CLARK SS: Encrustation of catheter materials in vitro. *J Urol* 108: 473, 1972
- PAINTER MR, BORSKI AA, TREVINO GS, et al: Urethral reaction to foreign objects. *J Urol* 106: 227, 1971
- HOWARD JE, THOMAS WC JR, SMITH LH, et al: A urinary peptide with extraordinary inhibitory powers against biological "calcification" (deposition of hydroxyapatite crystals). *Trans Assoc Am Physicians* 79: 137, 1966
- HOWARD JE, THOMAS WC JR, BARKER LM, et al: The recognition and isolation from urine and serum of a peptide inhibitor to calcification. *Johns Hopkins Med J* 120: 119, 1967
- HOWARD JE, THOMAS WC: Control of crystallization in urine. *Am J Med* 45: 693, 1968